Douglas Williams, Biogen Idec ($BIIB)
2012 pay package: $3.96 million
2011 pay package: $3.37 million
2012 Compensation: $657,865 in salary; $2.49 million in stock awards; $698,544 in incentive pay; $121,023 in other compensation
Douglas Williams served as CSO at Seattle Genetics ($SGEN) and CEO at ZymoGenetics before joining Biogen as R&D chief in 2011. Prior to his business career, he was on the faculties of the Indiana University School of Medicine and the Department of Laboratory Medicine at the Roswell Park Memorial Institute in Buffalo, New York.
The soft-spoken Williams may not have witnessed the birth of the multiple sclerosis fighter Tecfidera, but he shepherded the drug through its final stage of development to FDA approval in March 2013. It's Biogen's first novel drug approved by the FDA since Tysabri. Tecfidera is expected to blow past Tysabri, sales-wise, and it brought in $192 million by the end of the second quarter.
Biogen also has several blockbuster candidates moving up the pipeline. The company filed two hemophilia treatments for FDA approval in recent months: Eloctate, for hemophilia A, in early 2013; and Aprolix, its long-lasting hemophilia B candidate, at the end of 2012. Plegridy, another drug for multiple sclerosis, was submitted for FDA approval in May.
Special Report: Which Big Biotechs are hitting the gas pedal on R&D spending?
Biogen Idec advances blockbuster MS franchise on two key fronts
-- Skye Toor